Vet World   Vol.17   September-2024  Article - 13 

Research Article

Veterinary World, 17(9): 2062-2071

https://doi.org/10.14202/vetworld.2024.2062-2071

Myristica fragrans Houtt. methanol extract as a promising treatment for Cryptosporidium parvum infection in experimentally immunosuppressed and immunocompetent mice

Eman E. El Shanawany1, Faten Abouelmagd2, Noha Madbouly Taha3, Rabab S. Zalat4, Enas H. Abdelrahman5, and Eman H. Abdel-Rahman1
1. Department of Parasitology and Animal Diseases, National Research Centre, Dokki-Giza, Egypt.
2. Department of Medical Parasitology, Faculty of Medicine, Sohag University, Sohag, 82524, Egypt.
3. Department of Parasitology, Kasr Al-Ainy School of Medicine, Cairo University, Egypt.
4. Department of Parasitology, Theodor Bilharz Research Institute, Egypt.
5. Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, Egypt. 

Background and Aim: Cryptosporidiosis is a major waterborne disease affecting ruminants and humans worldwide. It causes diarrhea and neonatal mortality in buffalo calves, and watery diarrhea and mortality in children and immunodeficient patients. This study aimed to investigate the efficacy of Myristica fragrans methanolic extract in treatment of C. parvum infection in comparison with nitazoxanide (NZX) (a Food and Drug Administration-approved drug control) in immunosuppressed and immunocompetent mice. 

Materials and Methods: One hundred laboratory-bred male Swiss albino mice were equally divided into immunocompetent and immunosuppressed groups. Each group was further divided into five subgroups: (1) non-infected and non-treated control, (2) infected and non-treated control (infected with Cryptosporidium parvum oocysts 3 × 103), (3) NZX-treated (100 mg/kg, 200 μL/mouse), (4) M. fragrans Houtt. methanol extract-treated (500 mg/kg), and (5) combination-treated (NZX + M. fragrans extract). Number of oocysts/g of feces, serum immunoglobulin (Ig) G level, and interferon (IFN)-γ, and interleukin (IL)-4 levels were used to evaluate the therapeutic effect. 

Results: C. parvum oocyst shedding in stool samples was significantly decreased in all treatment groups, with 79.7%, 81.2 %, and 85.5 % reduction in immunocompetent mice treated with NZX, M. fragrans, and their combination, respectively. In immunosuppressed mice, oocyst shedding was reduced by 77.7%, 80.5 %, and 83.7 % upon NZX, M. fragrans, and their combination treatments, respectively. The serum IgG level was lowest in mice treated with a mixture of M. fragrans and NZX, followed by those treated with NZX, and was highest in mice treated with M. fragrans alone. Regarding cytokine levels, all groups treated with M. fragrans had low levels of IFN-γ and IL4 on day 21 post-infection. 

Conclusion: Collectively, the treatment of cryptosporidiosis with M. fragrans extract was successful in mice, as demonstrated by the measured parameters. M. fragrans reduced C. parvum oocyst shedding and serum IgG, IFN-γ, and IL-4 levels in immunocompetent and immunosuppressed mice. 

Keywords: Cryptosporidium parvum, gas chromatography-mass spectrometry, immunosuppressed mice and immunocompetent mice, Myristica fragrans Houtt., treatment.


How to cite this article: El Shanawany EE, Abouelmagd F, Taha NM, Zalat RS, Abdelrahman EH, and Abdel-Rahman EH (2024) Myristica fragrans Houtt. methanol extract as a promising treatment for Cryptosporidium parvum infection in experimentally immunosuppressed and immunocompetent mice, Veterinary World, 17(9): 2062-2071.

Received: 2024-05-10    Accepted: 2024-08-05    Published online: 2024-09-15

Corresponding author: Eman E. El Shanawany    E-mail: ee.elshanawany@hotmail.com

DOI: 10.14202/vetworld.2024.2062-2071

Copyright: Shanawany, et al. This article is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/ by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.